5 results for "Allan Relecom"
Showing 1–5 · 0.72 seconds · RSS
-
Journal Article
Antibody-Drug Conjugates in the Treatment of Metastatic Breast Cancer: The Emerging Questions of Sequence and Resistance
Metastatic breast cancer continues to present significant therapeutic challenges, necessitating ongoing exploration of innovative treatments. The use of antibody-drug conjugates (ADCs) represents an effective treatment strategy that combines the targeting capabilities of monoclonal antibodies with…
-
Journal Article
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
Abstract Immune checkpoint inhibitors provide considerable therapeutic benefit in a range of solid cancers as well as in a subgroup of hematological malignancies. Response rates are however suboptimal, and despite considerable efforts, predicting response to immune checkpoint inhibitors ahead of…
-
Journal Article
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
Abstract Introduction Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in…
-
Journal Article
Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report
Combined radioimmunotherapy is currently being investigated to treat patients with cancer. Anti-programmed cell death-1 (PD-1) immunotherapy offers the prospect of long-term disease control in solid tumors. Radiotherapy has the ability to promote immunogenic cell death leading to the release of…